ArticleDiscover oncology2025
Identification and characterization of cuproptosis related gene subtypes through multi-omics bioinformatics analysis in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Obovatol induces apoptosis in breast cancer by downregulating the PI3K/Akt pathway.Translational cancer research · 2026Article
- Integrated bioinformatics analysis identifies cuproptosis and ferroptosis gene signatures via subgroup clustering: Prognostic and therapeutic implications in breast cancer.Biochemistry and biophysics reports · 2025Article
- Article
- To Explore the Mechanism of Cuproptosis in Psoriasis Based on Bioinformatics and in vivo Experiments.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cuproptosis, a newly suggested mechanism of controlled cellular demise, which has been extensively associated with aspects of occurrence and development in breast cancer. The aim of this study was to conduct a comprehensive multi-group bioinformatics analysis based on the expression of cuproptosis-related genes (CRGs) to identify novel breast cancer subtypes to guide clinical practice. We collected TCGA-BRCA and GSE42568 datasets to investigate the expression patterns of CRGs in breast cancer. Consensus cluster analysis was performed to identify distinct subtypes. Subsequently, an investigation was carried out to examine the disparities between CRGclusters through functional enrichment analysis. Finally, we examined microsatellite instability, tumor mutation burden, drug sensitivity, infiltration of immune cells and cancer cell stemness across different CRGclusters. We identified two subtypes, where CRGcluster S2 exhibits a poorer prognosis compared to CRGcluster S1. Moreover, CRGcluster S2 demonstrated lower immune infiltration scores, higher cancer cell stemness index, and increased tumor mutation burden relative to CRGcluster S1, with the most frequently mutated gene being ATP7A. Notably, breast cancer chemotherapy drugs such as docetaxel, doxorubicin, and paclitaxel exhibited reduced sensitivity towards CRGcluster S2 when compared to CRGcluster S1. We have identified two CRGclusters in breast cancer that could serve as potential therapeutic targets and warrant further investigation in clinical trial studies for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.